Tag: delivering

The New Zealand dollar is up sharply on Tuesday. In the North American session, NZD/USD is trading at 0.6943, up 0.83% on the day. NZ consumer sentiment falls sharply Westpac Consumer sentiment slowed for a third straight quarter, and the Q1 release showed a sharp drop, falling from 99.1 to 92.1. The 100-level separates optimism […]

Meachers Global Logistics welcomed industrial researchers from Cambridge University to its Southampton headquarters for... Read more »

The post Meachers shows the way for delivering digital logistics appeared first on Logistics Business® Magazine.

An unusual attack using an open-source Python package installer called Chocolatey, steganography and Scheduled Tasks is stealthily delivering spyware to companies.

Every marketer faces different challenges. And, ever since 2020, the ways we've had to pivot, adjust campaigns, and address challenges has been unlike anything many of us have had to do before.

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Highlights
-- The group's turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million;

-- Sales coverage increased to around 10,500 hospitals and 2,110 pharmaceutical stores in the PRC;

-- Obtained an approval for the registration and commercialisation of the preservative-free unit-dose Moxifloxacin Hydrochloride Eye Drops in the PRC;

-- Significant progress in R&D program, 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage as the below:
SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021;
Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC);
Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC);

-- Holds a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents;

-- Completed the acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules.

Significant progression in Financial Performances

Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties. For the year ended 31 December 2021, the Group recorded a turnover growth of 67.4% to approximately HK$1,637.7 million as compared to approximately HK$978.1 million in 2020, indicating a strong recovery to the pre-COVID-19 operating level. In tandem with the increase of turnover, the Group achieved an increase of 58% in after-tax profit to approximately HK$346.0 million as compared to approximately HK$218.9 million in 2020.

Turnover of Ophthalmology and Surgical Segments Surged 60.6% and 72.6% respectively
The Group's turnover is primarily made up from the segments of Ophthalmology and Surgical (wound care and healing). The core products that are of current growth driver under each segment are:

1. Ophthalmology - Beifushu series (Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops and Shilishun(Iodized Lecithin Capsules); and

2. Surgical (Wound care and healing) - Beifuji series (Beifuji spray, Beifuji lyophilised powder and Beifuxin gel), Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules.

The sectoral turnover of Ophthalmology and Surgical is approximately 41.1% and 58.9% of the Group's turnover, respectively. The combined turnover of the Group's flagship biologics, Beifushu series and Beifuji series, the basic fibroblast growth factor (bFGF) based biologic drugs, represented about 84.3% of the Group's total turnover, of which Beifushu series and Beifuji series accounted for 26.1% and 58.2% of the Group's turnover, respectively. The remaining 15.7% of the Group's turnover is mainly contributed from sales of Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Shilishun Iodized Lecithin Capsules, Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules, collectively. Ophthalmology segment contributed approximately HK$673.3 million to the Group's turnover for the year ended 31 December 2021, representing an increase of 60.6% as compared to approximately HK$419.2 million in 2020. Surgical segment recorded a total turnover of approximately HK$964.4 million for the year ended 31 December 2021, representing an increase of 72.6% as compared to approximately HK$558.9 million in 2020. The increase was attributable to the resumption of clinical operations in hospitals to normalcy in the PRC and the expansion of sales.

The selling of Xalatan Eye Drops and Xalacom Eye Drops would be discontinued in 2022 that contributed approximately 2% to the Group's gross profit for the year ended 31 December 2021.

The Board proposed a final dividend of HK$0.055 (2020: HK$0.05) per ordinary share to be approved at the upcoming annual general meeting of the Company.

Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges. Our part of the world has been affected by extended lockdowns and border closures under COVID zero regime, even as other regions begun to reopen. Despite yet another difficult year inflicted by the pandemic of COVID-19 on us all, the tenacity, drive and leadership in our DNA was able to deliver greater stakeholder value. The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021. This is a testament that the Group's business is resilient and was able to recover swiftly to the pre-COVID-19 level after the normalcy of the clinical operations of hospitals resumed in the PRC since September 2020."

Significant Business Development Activities

The Group is committed to pragmatically investing in new products and technologies to strengthen the Group's product and R&D pipeline as near to mid-term growth driver in ophthalmology and long-term plan for new therapeutics in oncology. During the year under review, major investments in ophthalmic products are outlined as follows:

Investment in Ophthalmology

Significant progress for SkQ1's second phase 3 clinical trial
In 2018, the Group entered into a co-development agreement with Mitotech S.A. ("Mitotech") and Mitotech LLC for the United States Food and Drug Administration (the "US FDA") phase 3 clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease. As disclosed in the announcement of the Company dated 24 February 2021, positive outcome was achieved during second phase 3 clinical trial (VISTA-2). The clinical trial study repeated statistically significant positive results on key predefined secondary end-point (Central Corneal Fluorescein Staining). The Board is enthusiastic about the read-out of clearing of central staining of the cornea (defined as zero staining in central cornea), which reveals the potential of SkQ1 in addressing oxidative stress in dry eye diseases. Following the positive trial outcome of VISTA-2, Mitotech has planned a pivotal trial (VISTA-3), which will commence once Mitotech's management team has fully assessed there is no potential disruption to trial centres and patient recruitment during the ongoing COVID-19 pandemic. However, recent developments in Ukraine have led to governments and industries reacting to business relationships with Russia in a way that could potentially induce delays in Mitotech's VISTA clinical trial program.

HLX04-O approved for phase 3 clinical trial
In 2020, the Group entered into a co-development and exclusive license agreement with Shanghai Henlius Biotech, Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor ("anti-VEGF") as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration ("wet-AMD"). As at the date of 22 March 2022, the recombinant anti-VEGF humanised monoclonal antibody injection HLX04-O ("HLX04-O") for the treatment of wet-AMD has been approved to commence the phase 3 clinical trial in Australia, the United States, Singapore, Russia, Serbia and European Union countries such as Hungary, Spain, Latvia, the Czech Republic and Poland. Also, the first patient has been dosed in a phase 3 clinical study for HLX04-O for the treatment of wet-AMD in the PRC.

Ophthalmology business is expected to be further strengthened by the acquisition of Shilishun Iodized Lecithin Capsules

The successful acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules will enable the Group to strengthen its ophthalmology business.

Market Development

Robust Market Access Capability
Over the years, the Group has been relentlessly investing in establishing and strengthening its market access capability. As at 31 December 2021, the Group maintains a network of 43 regional sales offices in the PRC and a total number of about 1,265 sales and marketing representatives, out of which 64% are full-time employees and 36% are on contract basis or from appointed agents.

More Extensive Healthcare Network for Product Prescription
During the year under review, the Group's therapeutic products are being prescribed in more than 10,500 hospitals and medical providers, coupled with approximately 2,110 pharmaceutical stores, which are mainly located in the major cities, provinces and county cities in the PRC.

Further Investments to Strengthen Competitiveness and Customer Base
For achieving a sustainable traction on growth for currently marketed products as well as for near-term to mid-term new products being commercialised, the Group initiated investments to improve its competitiveness and widen its customer base under the following plans:

-- Investing in clinical observation programs for affirming additional clinical indications of its commercialised products;
-- Reaching out to market in lower-tier cities;
-- Cultivating pharmaceutical stores, where possible, as complementary sales channel; and
-- Building on-line platform for medical consultation and e-prescription for patients with chronic diseases under its healthtech initiative.

The Group has initiated its market access expansion to Southeast Asian countries by setting up a base and expanded its presence in Singapore since 2020.

Research and Development

The Group renewed its R&D's vision, emphasising the dedication to science and innovation, with a mission to develop therapeutics that would meet unmet clinical and/or commercial needs. The Group concurrently kick-started a 5-year (2021 to 2025) R&D's development plan to further strengthen its R&D capability and its position in Ophthalmology.

As at 31 December 2021, there are 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage. The 3 ophthalmology programs listed below are targeted as mid-term growth driver.

1. EB11-18136P: SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021

2. EB11-15120P: Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC)

3. EB12-20145P: Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC)

As at the date of this announcement, the Group has obtained a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents.

The Group currently has diversified its R&D resources to multiple research sites in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore which supports not only our pursuit for new therapeutics but also our acquisition of global talent.

Prospects

Looking ahead, the Group will continue to monitor the circumstances under the uncertainty of COVID-19 in 2022. Its strong team spirit and dynamic leadership have provided it with the capacity to navigate these turbulent times, and capture any opportunities in the ever changing world. The Group remains highly dynamic in delivering positive results in the coming year.

"COVID-19 remains a major concern in 2022 globally. We continue to monitor the situation and will take appropriate actions to overcome any unforeseen challenges. Barring the unforeseen circumstance, the Group remains focus on executing its plans and delivering progressive results. I would like to take this opportunity to express my sincere gratitude to all stakeholders, business associates and valued customers for the trust, support and cooperation accorded to us, and each and every member of the Group for their relentless efforts rendered in shaping the Group into being a progressive and promising pharmaceutical player.", said Mr. Patrick Ngiam.

Full version of Essex's FY2021 Annual Results Announcement can be downloaded at: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0322/2022032200780.pdf

About Essex Bio-Technology Limited (Stock Code: 1061.HK)
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun Iodized Lecithin Capsules etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Media Enquiry:
Strategic Financial Relations Limited (Website: http://www.sprg.com.hk)
Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320 yan.li@sprg.com.hk
Jill Cheung +852 2114 4870 jill.cheung@sprg.com.hk
Media: media@essex.com.cn

Investor Enquiry:
Investor Relations: investors@essex.com.cn


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEssex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

TOKYO, Mar 22, 2022 - (JCN Newswire) - HSM Advisory and Fujitsu Limited have published a joint research report on the current state and future of hybrid work, which sits at the convergence of the digital and real-world. The report introduces Fujitsu and HSM Advisory's Sustainable High Performance Model that highlights key success factors for hybrid work initiatives, offering a framework to enhance employee productivity, promote creativity, and deliver better customer experiences. In this joint report, HSM Advisory and Fujitsu introduce strategies for realizing effective hybrid working derived from the experiences and lessons learned during the past two years of the COVID-19 pandemic, which redefined the ways in which organizations work. The report concludes that holistic approach encompassing purpose, culture, management, autonomy, performance, and innovation proves essential to embedding effective hybrid working practices.
Video message from Lynda Gratton and Hiramatsu Hiroki: https://www.youtube.com/watch?v=bosMD9fY4OU&feature=youtu.be

You can watch the video message from Lynda Gratton and Hiramatsu Hiroki from the below.
Lynda Gratton, Professor of Management Practice at London Business School and founder of HSM Advisory comments "We are pleased to be working with our partner Fujitsu to conduct this very important study. Through a series of interviews and focus group sessions conducted as input to this report, we gained new insights into how companies and managers are responding to the shift to hybrid work."

Hiroki Hiramatsu, CHRO at Fujitsu Limited comments, "With our successful 'Work Life Shift' initiative, Fujitsu has demonstrated its global leadership in the development and execution of new work styles that empower employees to realize their purpose, as well as the company's. As we strive to make hybrid working a reality, we remain focused on building autonomy and mutual trust between employees and the company. This report reflects our hope that the efforts of Fujitsu and HSM Advisory will contribute to the wellbeing and creativity of organizations and serve as a model for other organizations exploring new ways of working."

Moving forward, HSM Advisory and Fujitsu will continue to research, demonstrate, and implement hybrid working models that improve employee wellbeing and bring together diverse talent to drive innovation in the workplace and beyond.

A paradigm shift in the ways we work

The onset of the COVID-19 pandemic has served as a catalyst for change, challenging our most basic assumptions about how, when, and where we work. In response, many organizations have shifted to hybrid working, as employees grapple with the challenges of collaborating effectively across differences in both time and place. At the same time, with many employees enjoying greater autonomy, some organizations have leveraged the freedoms and flexibility offered by hybrid working models as a way to stand out amidst an increasingly competitive global labor market.

Designing new ways of working that drive both performance and wellbeing now represents a key concern for organizations looking to attract and retain top talent.

Survey Report Summary

HSM Advisory and Fujitsu began a joint study in August 2021 to gain better insight into these themes. In this joint study, Fujitsu and HSM Advisory surveyed how leaders, employees, and organizations are responding to the challenges and opportunities of hybrid work. Adopting a cross-organizational, global approach, we have developed a Sustainable High Performance model to support organizations in the redesign of work.

Through this research, we hope to share best practice and insights into redesigning work.

The research, undertaken in partnership with HSM Advisory from August to November 2021, consisted of interviews with 9 Fujitsu Leaders and 46 Fujitsu employees, and 4 Fujitsu Client leaders. This was followed by a survey, shared broadly through Fujitsu and HSM networks, which gathered data about the experiences of an additional 200 people. Further insights were derived from 8 leaders from HSM advisory partnerships.

Notes to editors:
Fujitsu introduced its own "Work Life Shift" initiative in July 2020 to redefine working styles for thousands of its employees. As employees worked from home, Fujitsu aimed to ensure that their experience was empowering, productive and creative, with the goal of boosting innovation and delivering new value to customers.

About Fujitsu

Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.

About HSM Advisory

HSM Advisory is a specialist research and advisory group founded by Professor Lynda Gratton of the London Business School. Lynda is one of the world's leading thinkers on the future of work and organizational behavior. For more information, please see https://hsm-advisory.com/.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comHSM Advisory and Fujitsu Limited have published a joint research report on the current state and future of hybrid work, which sits at the convergence of the digital and real-world.

The AI-powered drone is the first military combat aircraft the country will produce in more than half a century

Could franchises like Final Fantasy be coming to mobile AR gaming?

Could a VR/AR adaptation of the deloved fantasy RPG be on the horizon? The 2022 Game Developer Conference (GDC) began earlier today in San Francisco, California, kicking off five days of industry-shaking announcements, round-table discussions, and various other content centered around video game development. A number of high-profile company’s have already begun teasing a handful […]

The post Final Fantasy Creator Square Enix Gets Serious About AR appeared first on VRScout.

ClearBank raised $230 million (£175 million). The investment was led by private equity advisory firm Apax Digital and brings ClearBank’s total funding to $627 million. ClearBank will use the funds to expand internationally, first in Europe, then into North America and Asia Pacific. Clearing and embedded banking technology company ClearBank raised $230 million (£175 million) this Read more...

The post U.K.-Based ClearBank Raises $230 Million appeared first on Finovate.

The post Qualcomm & Square Enix Partner to Create AR Games appeared first on Road to VR.

The Big Mouth spinoff gets at the business behind the business Continue reading… Coinsmart. Europe's Best Bitcoin...